Other analysts have also recently issued reports about the stock. Maxim Group set a $3.00 target price on shares of Actinium Pharmaceuticals and gave the company a buy rating in a research report on Wednesday, November 1st. Zacks Investment Research cut shares of Actinium Pharmaceuticals from a buy rating to a hold rating in a research report on Monday, January 15th. Finally, Roth Capital restated a buy rating and set a $6.00 target price on shares of Actinium Pharmaceuticals in a research report on Monday, October 23rd. Five analysts have rated the stock with a buy rating, The stock currently has a consensus rating of Buy and a consensus price target of $3.75.
Shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) traded down $0.01 during midday trading on Friday, hitting $0.59. 139,012 shares of the stock traded hands, compared to its average volume of 646,233. The stock has a market cap of $46.93, a PE ratio of -1.25 and a beta of 40.77. Actinium Pharmaceuticals has a 52-week low of $0.53 and a 52-week high of $1.68.
A hedge fund recently raised its stake in Actinium Pharmaceuticals stock. D.A. Davidson & CO. boosted its position in shares of Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) by 227.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 157,000 shares of the biotechnology company’s stock after purchasing an additional 109,000 shares during the period. D.A. Davidson & CO. owned about 0.20% of Actinium Pharmaceuticals worth $104,000 as of its most recent SEC filing.
COPYRIGHT VIOLATION NOTICE: “Actinium Pharmaceuticals (ATNM) Given a $3.00 Price Target at B. Riley” was first posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://ledgergazette.com/2018/02/17/actinium-pharmaceuticals-atnm-given-a-3-00-price-target-at-b-riley.html.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.